8 min read
Monthly FDA Guidance and Regulatory News Review - July 2026
This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...
Veristat is excited to attend the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop being sponsored by the ASA Biopharmaceutical Section in cooperation with the FDA Statistical Association.
This conference includes invited sessions co-chaired by statisticians from industry, academia, and the FDA over two days. In addition, short courses on related topics are offered the day prior to the workshop.
Many of the exciting topics that will be discussed at this event include:
To speak with a member of our biostatistical team either at the workshop or anytime that is convenient for you, simply fill out the form on the right hand side of this page.
"Operationalizing A Complex Adaptive Design | Accelerating A Go/No-Go Decision "
A clinical-stage biopharmaceutical company came to Veristat with a complex statistical methodology for running a phase II adaptive design trial with the goal of expediting a go/no-go decision for a specific patient population. The sponsor's challenge was that they didn't fully understand the complex methodology enough to explain it nor design the actual trial.
Learn how and why Veristat was able to implement the design and help the sponsor reach their go/no-go decision quickly.
8 min read
Aug 14, 2026 Veristat Blog
This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...
1 min read
Aug 12, 2026 Veristat Blog
China is rapidly becoming one of the most influential forces in global drug development—but bringing innovative...